Key Highlights

  • Shares are trading 1.43% lower at $3.11 on Wednesday, October 28, 2026, after a $3.16 close on October 23.
  • Short-interest data for the settlement date of August 31, 2026 show 10,874,649 shares short, 37.74% of float, or 18.9 days to cover.
  • Cash, equivalents and marketable securities were $220.0 million at June 30, against a market value of about $102.74 million.
  • Second-quarter net loss was $31.918 million on total revenue of $5.486 million.
  • Selling, general and administrative expense was $84.338 million in the first half of 2026.

LENZ Therapeutics Shares Slip: Why Is a Heavily Shorted Eye-Care Stock Drifting Lower?

LENZ Therapeutics (NASDAQ:LENZ) shares are trading 1.43% lower at $3.11 on Wednesday, October 28, 2026. No dated company release accompanies the move, which extends a slide from a $3.79 close on October 6 and a $5.96 close on September 4. Over 52 weeks the stock has fallen about 92%.

The company is a commercial-stage eye-health business whose product VIZZ (aceclidine ophthalmic solution 1.44%) won FDA approval on July 31, 2025 for presbyopia in adults. Sales began in the fourth quarter of 2025 through wholesalers and an ePharmacy partner that serves patients directly.

LENZ Short Interest: What Does 37.74% of Float Mean After the Autumn Decline?

Short-interest data for the settlement date of August 31, 2026 show 10,874,649 shares sold short, down 2.86% from 11,195,137 in the prior report. That equals 37.74% of float and 18.9 days of average volume to cover, which is a long period for a position to unwind.

A short position of this scale can amplify moves in either direction: purchases to cover can accelerate a rally, while continued selling can add to a decline. The figure does not indicate direction by itself. Larger daily falls in September included 10.57% on September 8 and 8.96% on September 23.

LENZ Second-Quarter Results: How Much Is VIZZ Selling Against a $39 Million Spending Quarter?

Net product sales were $1.736 million in the second quarter and $3.387 million for the first half. License revenue added $3.75 million in the quarter, taking total revenue to $5.486 million. Selling, general and administrative expense was $39.378 million for the quarter and $84.338 million for six months, including advertising of $11.4 million and $25.6 million. No research and development expense was recorded in either 2026 period, compared with $9.061 million in the second quarter of 2025.

The net loss was $31.918 million for the quarter and $73.406 million for six months, lifting the accumulated deficit to $300.5 million. Three wholesalers made up 39% of second-quarter product sales.

LENZ Cash Position: Does $220 Million Cover the Market Value and the Runway?

Cash and equivalents were $24.2 million and cash plus marketable securities were $220.0 million at June 30, with debt of $569,000. That compares with a market capitalisation of $102.74 million at the October 16 close, and the company said these resources support operations for at least 12 months from the filing date. Shares outstanding were about 31.42 million.

In June, Everest Medicines agreed to acquire the Greater China rights to VIZZ from CORXEL Pharmaceuticals. LENZ has received $15.0 million upfront and is eligible for $5.0 million on a China filing, $5.0 million on FDA approval and up to $85.0 million in further milestones, plus royalties. The company cited a possible need for more capital as commercialisation grows.

What to Watch Next: Will Third-Quarter Sales Show VIZZ Gaining Traction?

The next dated events are the third-quarter results, where product sales, spending and the cash balance can be compared with the June figures above, and the next short-interest release. Progress on the Greater China milestones is also in focus.